Loading clinical trials...

Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents | Clinical Trials | Clareo Health

COMPLETEDNA

Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents

A Prevalence and Multi-center Randomized Parallel-group Pragmatic Trial to Compare the Effectiveness of Standardized Skin Care Regimens on Skin Health in Nursing Home Residents

NCT02216526•PD Dr. Jan Kottner

View on ClinicalTrials.gov

Summary

Residents of institutional long-term care facilities are at high risk for developing skin and tissue diseases, e.g. xerosis cutis (including pruritus), infections (e.g., tinea pedis, candidiasis), chronic wounds or neoplastic changes (e.g. actinic keratosis, malignant melanoma) but there are few epidemiological figures about the actual frequencies of these conditions in nursing homes. Therefore, in the first part of this study we aim at measuring key dermatological conditions and associated health and functional status, and the skin care practice of aged nursing home residents ("prevalence study"). Basic skin care interventions are believed to reduce skin dryness and to enhance skin health. Thus, the second aim of this study is to investigate the effectiveness of two structured skin care regimens compared to the routine standard skin care on skin health in nursing home residents ("intervention study"). The study will be conducted in a random sample of seven out of approximately 300 institutional long term care facilities of the federal state of Berlin.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•"Prevalence study"
•Living in the nursing home at the time of data collection;
•Being 65+ years;
•Written informed consent (or by legal representative);
•Overall dry skin score (ODS) of 2 to 4 at the right and left leg;
•Willingness and ability to fulfil the study requirements.

Exclusion Criteria

•"Prevalence study"
•Residents at the end of life (dying persons).
•Any dermatological condition or skin affection, e.g. acute weeping, excoriated or inflammatory dermatitis, or skin treatment which may interfere with the study assessments at the discretion of the investigator;
•Any unstable acute or chronic pathology or condition that may interfere with the study conduct at the discretion of the investigator;
•Any use of topical drugs on the investigational areas two weeks prior to inclusion;
•Systemic application of corticosteroids, antihistamine or other anti-inflammatory drugs;
•Known allergy or intolerance to any ingredient of the study products, e.g. urea.

Locations (1)

Charité - Universitätsmedizin Berlin

Berlin, Germany

Key Dates

Start Date

September 1, 2014

Primary Completion Date

April 1, 2015

Completion Date

April 1, 2015

Last Updated

April 13, 2018

Enrollment

133

ACTUAL participants

Conditions

Xerosis Cutis

Interventions

Cetaphil® Restoraderm

OTHER

Excipial

OTHER

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933

Acneiform Eruption Due to ChemicalXerosis Cutis+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions